These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1749373)

  • 1. Food and Drug Administration approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1991 Dec; 40(50):881-2. PubMed ID: 1749373
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA approval of a fourth acellular pertussis vaccine for use among infants and young children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Nov; 47(43):934-6. PubMed ID: 9822368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Aug; 45(31):676-7. PubMed ID: 8778580
    [No Abstract]   [Full Text] [Related]  

  • 4. Food and Drug Administration approval of a second diphtheria and tetanus toxoids and acellular pertussis vaccine.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1992 Aug; 41(34):630-1. PubMed ID: 1501606
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Nov; 45(45):993-5. PubMed ID: 9005308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA approval of a second acellular pertussis vaccine for use among infants and young children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Feb; 46(5):110-1. PubMed ID: 9045038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Apr; 58(14):374-5. PubMed ID: 19373199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the Centers for Disease Control. FDA approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine.
    JAMA; 1992 Jan 22-29; 267(4):485. PubMed ID: 1729566
    [No Abstract]   [Full Text] [Related]  

  • 9. From the Centers for Disease Control. FDA approval of second diphtheria, tetanus toxoids, and acellular pertussis vaccine.
    JAMA; 1992 Oct; 268(14):1834, 1837. PubMed ID: 1404700
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Mar; 52(10):203-4. PubMed ID: 12653460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children--United States, 2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Jul; 51(26):574. PubMed ID: 12139185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1079-80. PubMed ID: 18830213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food and Drug Administration approval of use of Haemophilus influenzae type b conjugate vaccine reconstituted with diphtheria-tetanus-pertussis vaccine for infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Dec; 42(49):964-5. PubMed ID: 8246862
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Apr; 42(15):296-8. PubMed ID: 8479415
    [No Abstract]   [Full Text] [Related]  

  • 17. From the Centers for Disease Control and Prevention. FDA approval of a fourth acellular pertussis vaccine for use among infants and young children.
    JAMA; 1999 Jan; 281(3):226. PubMed ID: 9918467
    [No Abstract]   [Full Text] [Related]  

  • 18. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential impact of acceleration of the pertussis vaccine primary series for infants.
    Shinall MC; Peters TR; Zhu Y; Chen Q; Poehling KA
    Pediatrics; 2008 Nov; 122(5):1021-6. PubMed ID: 18977982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.